Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.66) by 12.12 percent. This is a 76.71 percent increase over losses of $(2.49) per share from the same period last year. The company reported quarterly sales of $12.648 million which beat the analyst consensus estimate of $8.520 million by 48.45 percent. This is a 331.67 percent increase over sales of $2.930 million the same period last year.